The U.S. Food and Drug Administration on Friday approved a new drug to treat Alzheimer’s disease.
Testing reportedly showed considerable success in helping patients with the debilitating condition.
The FDA said in a press release that it had approved the drug Leqembi for Alzheimer’s patients. The drug is “the second of a new category of medications approved for Alzheimer’s disease that target the fundamental pathophysiology of the disease,” the agency said.
Testing of the drug reportedly showed it having “a statistically significant reduction in brain amyloid plaque,” one of the chief signs of Alzheimer’s progression.